Literature DB >> 25469013

Obesity, fatty liver disease and intestinal microbiota.

Nur Arslan1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disorder that is increasing in prevalence with the worldwide epidemic of obesity. NAFLD is the hepatic manifestation of the metabolic syndrome. The term NAFLD describes a spectrum of liver pathology ranges from simple steatosis to steatosis with inflammation nonalcoholic steatohepatitis and even cirrhosis. Metabolic syndrome and NAFLD also predict hepatocellular carcinoma. Many genetic and environmental factors have been suggested to contribute to the development of obesity and NAFLD, but the exact mechanisms are not known. Intestinal ecosystem contains trillions of microorganisms including bacteria, Archaea, yeasts and viruses. Several studies support the relationship between the intestinal microbial changes and obesity and also its complications, including insulin resistance and NAFLD. Given that the gut and liver are connected by the portal venous system, it makes the liver more vulnerable to translocation of bacteria, bacterial products, endotoxins or secreted cytokines. Altered intestinal microbiota (dysbiosis) may stimulate hepatic fat deposition through several mechanisms: regulation of gut permeability, increasing low-grade inflammation, modulation of dietary choline metabolism, regulation of bile acid metabolism and producing endogenous ethanol. Regulation of intestinal microbial ecosystem by diet modifications or by using probiotics and prebiotics as a treatment for obesity and its complications might be the issue of further investigations.

Entities:  

Keywords:  Dysbiosis, Nonalcoholic fatty liver disease; Intestinal microbiota; Obesity

Mesh:

Year:  2014        PMID: 25469013      PMCID: PMC4248188          DOI: 10.3748/wjg.v20.i44.16452

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  127 in total

Review 1.  Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis.

Authors:  Dennis E Vance
Journal:  Curr Opin Lipidol       Date:  2008-06       Impact factor: 4.776

Review 2.  Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?

Authors:  Eduardo Esteve; Wifredo Ricart; Jose-Manuel Fernández-Real
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-09       Impact factor: 4.294

3.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

4.  Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4.

Authors:  G L Su; R D Klein; A Aminlari; H Y Zhang; L Steinstraesser; W H Alarcon; D G Remick; S C Wang
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

5.  A role for mitochondria in NLRP3 inflammasome activation.

Authors:  Rongbin Zhou; Amir S Yazdi; Philippe Menu; Jürg Tschopp
Journal:  Nature       Date:  2010-12-01       Impact factor: 49.962

6.  Role of snail activation in alcohol-induced iNOS-mediated disruption of intestinal epithelial cell permeability.

Authors:  Christopher B Forsyth; Yueming Tang; Maliha Shaikh; Lijuan Zhang; Ali Keshavarzian
Journal:  Alcohol Clin Exp Res       Date:  2011-04-27       Impact factor: 3.455

7.  The gut microbiota as an environmental factor that regulates fat storage.

Authors:  Fredrik Bäckhed; Hao Ding; Ting Wang; Lora V Hooper; Gou Young Koh; Andras Nagy; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

8.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 9.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

Review 10.  The human gut microbiome: a review of the effect of obesity and surgically induced weight loss.

Authors:  Timothy E Sweeney; John M Morton
Journal:  JAMA Surg       Date:  2013-06       Impact factor: 14.766

View more
  43 in total

Review 1.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 2.  Pediatric Nonalcoholic Fatty Liver Disease: the Rise of a Lethal Disease Among Mexican American Hispanic Children.

Authors:  Monica M Betancourt-Garcia; Armando Arguelles; Jorge Montes; Ambrosio Hernandez; Manish Singh; R Armour Forse
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

Review 3.  Pediatric Non-alcoholic Fatty Liver Disease.

Authors:  Vikas Uppal; Sana Mansoor; Katryn N Furuya
Journal:  Curr Gastroenterol Rep       Date:  2016-05

4.  Interaction between dietary lipids and gut microbiota regulates hepatic cholesterol metabolism.

Authors:  Robert Caesar; Heli Nygren; Matej Orešič; Fredrik Bäckhed
Journal:  J Lipid Res       Date:  2016-01-18       Impact factor: 5.922

Review 5.  The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection.

Authors:  Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

Review 6.  Mechanisms and consequences of intestinal dysbiosis.

Authors:  G Adrienne Weiss; Thierry Hennet
Journal:  Cell Mol Life Sci       Date:  2017-03-28       Impact factor: 9.261

7.  Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome.

Authors:  Jayshree Mishra; Raj K Verma; Gianfranco Alpini; Fanyin Meng; Narendra Kumar
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

Review 8.  Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease.

Authors:  Syeda Momna Ishtiaq; Haroon Rashid; Zulfia Hussain; Muhammad Imran Arshad; Junaid Ali Khan
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 9.  Current Understanding of Dysbiosis in Disease in Human and Animal Models.

Authors:  Arianna K DeGruttola; Daren Low; Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

Review 10.  Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.

Authors:  Jordan E Lake; Turner Overton; Susanna Naggie; Mark Sulkowski; Rohit Loomba; David E Kleiner; Jennifer C Price; Kara W Chew; Raymond T Chung; Kathleen E Corey
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-16       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.